Published in AIDS Weekly, February 20th, 2006
The vaccine, based on exclusive technology codeveloped by CEO Liang Qiao, an associate professor at Loyola University Chicago's Stritch School of Medicine, targets infection in mucosal tissues, the first type of tissue attacked by HIV.
The studies showed that the vaccine at low, medium and high doses did not have any side effects on the central nervous system, the cardiovascular system or the respiratory system of the animals. No significant differences on blood cells...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.